REGENXBIO prices $100M public offering of common stock and pre-funded warrants

REGENXBIO Inc.

Offering of 10,003,889 shares at $9.00/share and 1,111,111 pre-funded warrants at $8.9999 each.
Gross proceeds ~$100M; net proceeds ~$107.8M after underwriters' full exercise of 1,667,250 option shares.
Underwriters: Morgan Stanley, J.P. Morgan, Leerink Partners, Mizuho Securities.
Expected to close July 20, 2026, subject to customary conditions.
Pre-funded warrants have $0.0001 exercise price, exercisable immediately, no expiration.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.